Elevated systemic FGF23 levels are associated with poor liver disease prognosis [39], while the transforming growth factor (TGF)-β, also bone-derived, inhibits hepatocyte proliferation and promotes fibrosis [31,40]. Here, TGFB1 is linked to liver disorder.